Growing university research and development is likely to boost the global aptamers market over the forecast period. AstraZeneca, a pharmaceutical and biotech business, announced in March 2021 that it has conjugate extended its oligonucleotide drug delivery agreement with Aptamer Group, a biotechnology company. They will conduct research and find innovative targeting aptamers to deliver medication molecules to the target renal cells as part of this cooperation. Aptamer limitations are the primary issues impeding the growth of the global aptamers market. For example, Aptamers are well-established therapeutic molecules with excellent specificity and affinity to their target, equivalent to monoclonal antibodies, according to research presented in Role of New Drug Delivery Vehicles in Nan Biomedicine Article in August 2019. Aptamers offer benefits over antibodies, but they also have disadvantages that have limited their clinical application as a therapeutic agent.
According to Coherent Market Insights, the global Aptamers Market is estimated to be valued at US$ 5,291.8 million in 2022 and is expected to exhibit a CAGR of 18.4% during the forecast period (2022-2030).
Prominent Players in the Aptamers Industry:
1. Ophthotech Corporation
IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.
2. Aptamer Sciences, Inc.
Aptamer Sciences, Inc. 1 Founded in April 2011 by the best aptamer experts in Korea under the banner of Bio Company. Based on the globally competitive Aptamer Technology Platform, they are an R & D-based bio venture company that develops innovative therapeutics and diagnostic technologies that are difficult to develop with protein and Genome-based biomaterials.
3. Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
4. Aptagen LLC
Aptagen, LLC is a global leader in aptamer development with over 25 years of experience generating high affinity and specifically-binding aptamers for small molecules, proteins, cells, and tissues. We produce state-of-the-art target-recognition elements for diagnostics, therapeutics, and bio-industrial applications. The company is headquartered in Pennsylvania, U.S.
5. Aptus Biotech S.L.
Aptus Biotech is a biotech start-up founded in 2010 from a collaboration agreement with the Ramon y Cajal Hospital Foundation. The company was founded in 2010, headquartered in Spain.
6. Base Pair Biotechnologies
Base Pair provides custom aptamer development services and catalog aptamers. Scientists at Base Pair Biotechnologies have been studying aptamers and developing them on a research basis since 2004 and began recently offering these services commercially. With a patent pending multiplexed approach we can develop custom aptamers at unprecedented time and cost. The company is headquartered in Texas, U.S.
7. AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
8. Agilent Technologies, Inc.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab (consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics. The comp any was founded in 1999.
*Definition- Aptamers are oligonucleotide sequences that can recognise target proteins with the same affinity and specificity as antibodies. Aptamers are single-stranded artificial nucleotides with a low molecular weight of 5-40k Dalton that produce a particular three-dimensional shape.
